Molecular therapy for the treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Recently, a number of new drugs targeting molecular mechanisms involved in liver cell transformation have entered into clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Greten, T F, Korangy, F, Manns, M P, Malek, N P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634687/
https://www.ncbi.nlm.nih.gov/pubmed/19018262
http://dx.doi.org/10.1038/sj.bjc.6604784
Descripción
Sumario:Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Recently, a number of new drugs targeting molecular mechanisms involved in liver cell transformation have entered into clinical trials and led to encouraging results. In this review we summarise this data and point to a number of new compounds, which are currently being tested and can potentially broaden our therapeutic arsenal even further.

Ejemplares similares